読み込み中
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
終値時点
$6.77
−$0.17 · -2.45%
時間外
$6.77
$0.00 · 0.00%
10月12日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
日中レンジ
現在 $6.77
52週レンジ
現在 $6.77
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
23
割高
センチメント
61
強気
リスク
71
高リスク
モメンタム
64
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
日中レンジ
現在 $6.77
52週レンジ
現在 $6.77
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 25.1万 USD | 3349.2万 USD | 493.1万 USD | 200.2万 USD |
| 売上原価 | 259.7万 USD | — | — | — | — |
| 粗利益 | −259.7万 USD | 25.1万 USD | 3349.2万 USD | 493.1万 USD | 200.2万 USD |
| 研究開発 | 6954万 USD | 5032.8万 USD | 5025.1万 USD | 4398.4万 USD | 4241万 USD |
| 販売・一般管理 | 2027万 USD | 1720.5万 USD | 1391.2万 USD | 2077.6万 USD | 1286.4万 USD |
| 営業費用 | 8801.3万 USD | 6753.3万 USD | 6416.3万 USD | 6476万 USD | 5527.4万 USD |
| 受取利息 | 595.9万 USD | 534.9万 USD | 253.5万 USD | 129.4万 USD | — |
| 減価償却費と償却費 | 259.7万 USD | 243.1万 USD | 226.6万 USD | 115.8万 USD | 24.8万 USD |
| 営業利益 | −9061万 USD | −6728.2万 USD | −3067.1万 USD | −5982.9万 USD | −5327.2万 USD |
| 純利益 | −8386.5万 USD | −5849.3万 USD | −2769.6万 USD | −5838.8万 USD | −7182.5万 USD |
会社概要が更新されました 2026年10月13日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは4件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI790.89万0.00%2.3兆 USD0.03%$381.57-0.10%
iShares Russell 2000 ETFIWM336.95万0.00%787.4億 USD0.19%$277.9-0.37%
Vanguard Extended Market ETFVXF304.14万0.00%954億 USD0.05%$233.52-0.63%
Simplify Propel Opportunities ETFSURI70.34万0.92%7606.44万 USD2.82%$17.2565+0.23%
iShares Micro-Cap ETFIWC41.91万0.03%13.17億 USD0.60%$181.66-0.73%
iShares Russell 2000 Growth ETFIWO34.36万0.00%139.17億 USD0.24%$353.71-0.86%
Franklin Small Cap Enhanced ETFFSML30.69万0.20%1.51億 USD0.45%$28.90-0.46%
Vanguard Russell 2000 ETFVTWO30万0.00%180億 USD0.06%$112.27-0.35%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFSimplify Propel Opportunities ETFSURIiShares Micro-Cap ETFIWCiShares Russell 2000 Growth ETFIWOFranklin Small Cap Enhanced ETFFSMLVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
